MLTX Investor with Losses Encourages to Contact Firm by Dec. 15 Deadline SAN FRANCISCO , Dec. 3, 2025 /PRNewswire/ -- Global plaintiffs' rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX) is December 15, 2025 . "In specialized biotech cases, the core legal question is often whether the company's claims about the study match the reality of the clin ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, particularly related to the company's clinical data and the performance of its investigational drug sonelokimab [1][2][5]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients and differentiation from competitors [4]. - Allegations suggest that the clinical data and the Nanobody structure of sonelokimab did not provide a superior clinical benefit, raising concerns about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Insights - Class actions have been initiated on behalf of stockholders of Cepton, Inc. and MoonLake Immunotherapeutics, with specific deadlines for investors to petition the court to serve as lead plaintiff [1] MoonLake Immunotherapeutics - The lawsuit alleges that MoonLake Immunotherapeutics misled investors regarding its drug candidate sonelokimab (SLK), claiming it was superior to competing monoclonal antibodies [6] - The complaint states that MoonLake and its executives promoted SLK's Nanobody structure as having unique clinical advantages while failing to disclose it targeted the same molecules as UCB's BIMZELX and had no proven superiority [6] - Following the announcement of Phase 3 results on September 28, 2025, which showed SLK did not match BIMZELX's efficacy, MoonLake's stock fell nearly 90%, resulting in significant investor losses [6] - On September 29, 2025, MoonLake filed a current report with the SEC indicating that intercurrent events in the higher-than-expected placebo arm prevented the study from achieving statistical significance [6] - The stock plummeted 89.9% on September 29, 2025, following this news [6] Cepton, Inc. - The lawsuit against Cepton alleges that defendants made materially false and misleading statements and failed to disclose tax fraud and bribery to cover it up [6] - The complaint claims that as a result of these actions, the legal risks facing the company were understated, leading to materially false and misleading statements about its business and operations [6] - Investors suffered damages when the true details of the situation became public [6]

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

MLTX COURT ALERT: MoonLake Immunotherapeutics Investors are Notified the Compay has been Sued for Securities Fraud and are Notified to Contact BFA Law by December 15December 02, 2025 3:33 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 2, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violat ...

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit alleges that the defendants made false and misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements in securities class actions, including the largest settlement against a Chinese company and significant recoveries for investors in recent years [4].

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics, Inc. centers on allegations that the company misrepresented the clinical efficacy of its product SLK compared to traditional monoclonal antibodies, particularly BIMZELX, leading to significant investor losses [2][3]. Legal Allegations - The lawsuit claims that MoonLake failed to disclose that SLK and BIMZELX share the same molecular targets (interleukin-17, or IL-17), which undermines the claimed competitive advantage of SLK [3]. - Allegations include that MoonLake misrepresented the Nanobody structure's ability to provide superior clinical efficacy, specifically in treating hidradenitis suppurativa (HS) [3]. - The stock price of MoonLake fell dramatically from $61.99 to $6.24, representing a 90% loss, following the disclosure of these issues [3]. Investor Actions - Hagens Berman is actively advising investors who purchased MLTX shares during the Class Period (March 10, 2024, through September 29, 2025) and suffered substantial losses due to the alleged undisclosed trial flaws [4]. - The deadline for investors to move the Court for appointment as lead plaintiff in the securities class action lawsuit is December 15, 2025 [1][4]. Firm Background - Hagens Berman is a global plaintiffs' rights law firm that has secured over $2.9 billion in settlements for investors in similar cases [4][8].

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15December 01, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the f ...

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Accessibility StatementSkip Navigation Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and ou ...

Accessibility StatementSkip Navigation PHILADELPHIA, Dec. 1, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...